Related Experiment Video
Updated: Jul 5, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Multicenter evaluation of vancomycin dosing: emphasis on obesity
Ronald G Hall1, Kenna D Payne, Amy M Bain
1Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA. ronald.hall@ttuhsc.edu
The American Journal of Medicine
|May 27, 2008
Summary
Obese patients frequently receive inadequate vancomycin dosing, increasing risks. Weight-based dosing is crucial for effective treatment and better clinical outcomes in obesity.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Pharmacy
Background:
- Limited data exists on antimicrobial dosing in obese individuals.
- Evidence suggests vancomycin dosing should be based on actual body weight.
Purpose of the Study:
- To evaluate vancomycin dosing adequacy in patients stratified by body mass index.
- To assess the impact of obesity on achieving target vancomycin doses.
Main Methods:
- Retrospective analysis of 421 patients receiving vancomycin across two medical centers.
- Patients stratified by body mass index (BMI) and analyzed for dosing adequacy (>or=10 mg/kg/dose and >or=15 mg/kg/dose).
- Inclusion criteria: BMI stratification, age >=18, creatinine clearance >=60 mL/min, vancomycin for >=36 hours.
Main Results:
- Obese patients had significantly lower rates of adequate initial vancomycin dosing (27.7%) compared to underweight (100%), normal weight (99%), and overweight (93.9%) patients.
- Only 0.6% of obese patients received the recommended >or=15 mg/kg/dose, versus 97% of underweight patients.
- Pharmacists failed to correct inadequate dosing in most cases, with only 3.3% of regimens adjusted within 24 hours.
Conclusions:
- Obese patients routinely receive inadequate empiric vancomycin dosing.
- Weight-based dosing strategies are essential to prevent subtherapeutic concentrations and improve patient outcomes.
- Further research and interventions are needed to optimize vancomycin dosing in obesity.
Related Concept Videos
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...